Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?

Journal of Hepatology

Volumn 63, Issue 4, 2015, Pages 779-782

  Grebely, Jason ^a   Haire, Bridget ^a   Taylor, Lynn E ^b   Macneill, Paul ^c   Litwin, Alain H ^d   Swan, Tracy ^e   Byrne, Jude ^f,g   Levin, Jules ^h   Bruggmann, Philip ⁱ   Dore, Gregory J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Treatment Action Group   (United States)

^f International Network of People Who Use Drugs   (Australia)

^g Australian Injecting and Illicit Drug Users League (AIVL)   (Australia)

^h National AIDS Treatment Advocacy Project   (United States)

ⁱ Arud Centres for Addiction Medicine   (Switzerland)

Author keywords

Adherence; Drug users; HCV; IFN free; Injecting; Injection; PWID

Indexed keywords

ALCOHOL; ANTIVIRUS AGENT;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG USE; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; MEDICAID; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; REVIEW; ALCOHOLISM; HEALTH CARE DELIVERY; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION;

ALCOHOLICS; ANTIVIRAL AGENTS; DRUG USERS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; PATIENT SELECTION;

EID: 84941942912     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.06.014     Document Type: Editorial

References (33)

1. N.S. Reau, and D.M. Jensen Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology 59 2014 1246 1249
2. S. Barua, R. Greenwald, J. Grebely, G.J. Dore, T. Swan, and L.E. Taylor Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States Ann Intern Med 2015 10.7326/M15-0406 [Epub ahead of print]
3. AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C. 2015 [cited 2015 January 18]; Available from: www.hcvguidelines.org.
4. European Association for Study of L EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 60 2014 392 420
5. N. Daniels Justice, health, and healthcare Am J Bioeth 1 2001 2 16
6. D.A. Asch, and P.A. Ubel Rationing by any other name N Engl J Med 336 1997 1668 1671
7. B.J. Russell Health-care rationing: critical features, ordinary language, and meaning J Law Med Ethics 30 2002 82 87
8. A.R. Jonsen Bentham in a box: technology assessment and health care allocation Law Med Health Care 14 1986 172 174
9. J. Grebely, and G.J. Dore What is killing people with hepatitis C virus infection? Semin Liver Dis 31 2011 331 339
10. A.J. van der Meer, H. Wedemeyer, J.J. Feld, J.F. Dufour, S. Zeuzem, B.E. Hansen, and et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population JAMA 312 2014 1927 1928
11. N.K. Martin, P. Vickerman, J. Grebely, M. Hellard, S.J. Hutchinson, V.D. Lima, and et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals Hepatology 58 2013 1598 1609
12. P.K. Nelson, B.M. Mathers, B. Cowie, H. Hagan, D. Des Jarlais, D. Horyniak, and et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews Lancet 378 2011 571 583
13. B. Hajarizadeh, J. Grebely, and G.J. Dore Epidemiology and natural history of HCV infection Nat Rev Gastroenterol Hepatol 2013
14. J. Grebely, J. Robaeys, R. Bruggmann, A. Aghemo, M. Backmund, J. Bruneau, and et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs Int J Drug Policy 2015 10.1016/j.drugpo.2015.07.005 [Epub ahead of print]
15. G. Robaeys, J. Grebely, S. Mauss, P. Bruggmann, J. Moussalli, A. De Gottardi, and et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs Clin Infect Dis 57 2013 S129 S137
16. M. Hellard, R. Sacks-Davis, and J. Gold Hepatitis C treatment for injection drug users: a review of the available evidence Clin Infect Dis 49 2009 561 573
17. E. Aspinall, S. Corson, J. Doyle, J. Grebely, S.J. Hutchinson, G.J. Dore, and et al. Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis Clin Infect Dis 2012
18. R.B. Dimova, M. Zeremski, I.M. Jacobson, H. Hagan, D.C. Des Jarlais, and A.H. Talal Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis Clin Infect Dis 56 2013 806 816
19. M.P. Manns, H. Wedemeyer, and M. Cornberg Treating viral hepatitis C: efficacy, side effects, and complications Gut 55 2006 1350 1359
20. B.S. Anand, S. Currie, E. Dieperink, E.J. Bini, H. Shen, S.B. Ho, and et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study Gastroenterology 130 2006 1607 1616
21. P. Bruggmann, M. Dampz, T. Gerlach, L. Kravecz, and L. Falcato Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study Drug Alcohol Depend 110 2010 167 171
22. NIH National institutes of health consensus development conference panel statement: management of hepatitis C Hepatology 26 1997 2S 10S
23. B.R. Edlin, K.H. Seal, J. Lorvick, A.H. Kral, D.H. Ciccarone, L.D. Moore, and et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 345 2001 211 215
24. National Institutes of H. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002 Hepatology 36 2002 S3 S20
25. WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection 2014 World Health Organization Geneva, Switzerland
26. A. Mangia, M. Kugelmas, G.T. Everson, F. Hinestrosa, J. Ma, J. McNally, and et al. Virologic response rates to sofosbuvir-containing regimens are similar in patients with and without traditional negative predictive factors: a retrospective analysis of phase 3 data Hepatology 58 2013 752A
27. Jacobson IM, Kwo PY, Kowdley KV, Yang JC, Zhu Y, Hyland RH, et al. Virologic response rates to all oral fixed-dose combination ledipasvir/sofosbuvir regimens are similar in patients with and without traditional negative predictive factors in phase 3 clinical trials. AASLD: The Liver Meeting®; 2014 November 7-11, 2014; Boston, MA; 2014.
28. Puoti M, Cooper C, Sulkowski M, Foster GR, Berg T, Villa E, et al. ABT-450/r/ombitasvir + dasabuvir with or without ribavirin in HCV genotype 1-infected patients receiving stable opioid substitution treatment: pooled analysis of efficacy and safety in phase 2 and phase 3 trials. AASLD: The Liver Meeting®; 2014 November 7-11, 2014; Boston, MA; 2014.
29. J. Lalezari, J.G. Sullivan, P. Varunok, E. Galen, K.V. Kowdley, V. Rustgi, and et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine J Hepatol 63 2015 364 369
30. F. Carrat, F. Bani-Sadr, S. Pol, E. Rosenthal, F. Lunel-Fabiani, A. Benzekri, and et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial JAMA 292 2004 2839 2848
31. R.T. Chung, J. Andersen, P. Volberding, G.K. Robbins, T. Liu, K.E. Sherman, and et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459
32. R. Jurgens, J. Csete, J.J. Amon, S. Baral, and C. Beyrer People who use drugs, HIV, and human rights Lancet 376 2010 475 485
33. N.K. Martin, P. Vickerman, A. Miners, G.R. Foster, S.J. Hutchinson, D.J. Goldberg, and et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations Hepatology 55 2012 49 57